Heart Failure Pharmacology
Sort by:
ACC 2022 Conference Coverage
ACC 2022: Diagnostic Approach in Patients With Left Ventricular Hypertrophy
FEATURING
Michelle Kittleson
- 374 views
- April 21, 2022
- 4
1st Women’s Heart and Vascular Symposium
The Cancer Connection: Cardiovascular Disease & Breast Cancer
FEATURING
Gautam Kedia
- 373 views
- January 20, 2020
- 5
UChicago Medicine
Not so Strong with the Force: Cardiac Myosin Inhibitor Therapy in Hypertrophic Cardiomyopathy
FEATURING
Gene Kim
- 363 views
- March 12, 2024
- 1
NYU Langone
SUB-Q vs. Transvenous ICD for Sudden Cardiac Death Prevention: Why and Who?
FEATURING
Lior Jankelson
- 359 views
- February 22, 2023
- 4
Canadian Collaborative Research Network
State of the Heart 2023 Session 1 Panel Discussion
- 357 views
- July 26, 2023
- 2
Canadian Collaborative Research Network
Vericiguat: Beyond the Four Pillars
FEATURING
Milan Gupta
- 353 views
- August 31, 2022
- 2
CME Outfitters
Hypertrophic Cardiomyopathy: Obstruction and Symptoms
FEATURING
Steve Ommen
- 352 views
- July 31, 2023
- 3
American College of Cardiology
Management of Patients With HFpEF: EMPEROR-Preserved Trial
- 351 views
- February 15, 2022
- 5
American College of Cardiology
ESC Congress 2022: DANCAVAS, REVIVED-BCIS2, ADVOR, ALL-HEART, and DELIVER Trials
- 348 views
- September 20, 2022
- 5
Northwestern Medicine: 13th Annual Heart Failure Symposium
Prevention of CVD and HF in Type 2 Diabetics
FEATURING
Donald M. Lloyd-Jones
- 345 views
- December 11, 2018
- 1
Yale School of Medicine
ACC 21 Highlights: Angiotensin Receptor Neprilysin Inhibition Following Acute MI (PARADISE-MI) Trial
FEATURING
Rohan Khera
- 340 views
- June 14, 2021
- 1
Diabetes Updates
SGLTi and Heart Failure Prevention
FEATURING
Peter Gaede
- 339 views
- October 23, 2019
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Approaches to Treating Diabetes that Reduce CV Events: How Effective Are DPP-4 Inhibitors, GLP1-Receptor Agonists and SGLT-2 Inhibitors in Reducing MACE and Preventing HF Events?
FEATURING
Jia Shen
- 339 views
- February 5, 2021
- 4
ACC 2024 Insights
ACC 2024 Insights: Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound and Durable Reductions In APOC-3 and Triglycerides (TG) in Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results
FEATURING
Daniel Gaudet
- 337 views
- April 16, 2024
- 3